SkinBioTherapeutics (LON:SBTX) Shares Up 7.9% – What’s Next?

Shares of SkinBioTherapeutics plc (LON:SBTX) rose 7.9% during mid-day trading on Friday . The stock traded as high as GBX 12.50 and last traded at GBX 12.13. 852,400 shares traded hands during trading, a decline of 78% from the average session volume of 3,837,103 shares. The stock had previously closed at GBX 11.25.

SkinBioTherapeutics Price Performance

The firm has a market capitalization of £29.16 million, a P/E ratio of -39.15 and a beta of 0.12. The company has a 50 day moving average of GBX 9.83 and a 200-day moving average of GBX 12.16. The company has a current ratio of 6.14, a quick ratio of 10.01 and a debt-to-equity ratio of 11.77.

SkinBioTherapeutics (LON:SBTX) last issued its quarterly earnings data on Monday, June 8th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. The firm had revenue of GBX 217 million during the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.